Ending the Arms Race: Ten Priorities for Fixing the Commercial Model
The drug industry has seen a massive shift in who influences prescription, payment, and consumption decisions. But corporate capabilities and tactics haven’t kept pace with these new market realities.
• By Holly Fogle, Alexander Petersen, and Christopher Simon
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.